In 81 analysed patients with prostate cancer on ADT, oxybutynin 2.5 mg and 5 mg cut hot flashes/day by 4.77 (P=.02) and 6.89 (P<.001) vs 2.15 with placebo at 6 weeks; hot flash score fell only significantly at 5 mg. No treatment-related grade 3+ AEs.
RCTn = 88
Stish et al. Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer